الصفحة الرئيسية>>Signaling Pathways>> TGF-β / Smad Signaling>> PKC>>Ro 31-8220

Ro 31-8220 (Synonyms: Bisindolylmaleimide IX)

رقم الكتالوجGC17322

Ro 31-8220 هو مثبط قوي لـ PKC ، مع IC50s من 5 و 24 و 14 و 27 و 24 و 23 نانومتر لـ PKCα و PKCβI و PKCβII و PKCγ و PKCε ودماغ الفئران PKC ، على التوالي

Products are for research use only. Not for human use. We do not sell to patients.

Ro 31-8220 التركيب الكيميائي

Cas No.: 125314-64-9

الحجم السعر المخزون
10mg
103٫00
Please Inquire
50mg
295٫00
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of Ro 31-8220

Ro 31-8220 is a selective inhibitor of protein kinase C (PKC) with IC50 values of 5, 24, 14, 27, and 24 nM for PKC α, PKC βI, PKC βII, PKC γ and PKC ε, respectively [1].

PKC is a monomeric Ca2+- and phospholipid-dependent Ser/Thr protein kinases and plays an important role in growth factor-activated signaling and malignant transformation.

Ro 31-8220 is a selective inhibitor of PKC. Also, Ro 31-8220 increased growth factor-stimulated expression of c-Jun but inhibited MKP-1 and c-Fos expression. Ro-31-8220 strongly stimulated the stress-activated protein kinase JNK1 in a PKC-independent way [2]. In peripheral blood mononuclear cells, Ro 31-8220 inhibited the production of mitogen-induced interleukin (IL) -2 and IL-2-dependent T lymphoblast proliferation with IC50 values of 80 and 350 nM, respectively. Also, Ro 31-8220 (400 nM) inhibited IL-2Rα (CD25) expression by 27%, which suggested that Ro 31-8220 inhibited early and late T cell activation [3].

In rat adipocytes and L6 myotubes, RO 31-8220 activated c-Jun N-terminal kinase (JNK) and glycogen synthase (GS) and stimulated glucose incorporation into glycogen. While, RO 31-8220 inhibited the activity of extracellular response kinases 1 and 2 (ERK1/2) in a PKC-independent way [4].

References:
[1].  Wilkinson SE, Parker PJ, Nixon JS. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J, 1993, 294 ( Pt 2): 335-337.
[2].  Beltman J, McCormick F, Cook SJ. The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase. J Biol Chem, 1996, 271(43): 27018-27024.
[3].  Geiselhart L, Conti DJ, Freed BM. RO 31-8220, a novel protein kinase C inhibitor, inhibits early and late T cell activation events. Transplantation, 1996, 61(11): 1637-1642.
[4].  Standaert ML, Bandyopadhyay G, Antwi EK, et al. RO 31-8220 activates c-Jun N-terminal kinase and glycogen synthase in rat adipocytes and L6 myotubes. Comparison to actions of insulin.

Protocol of Ro 31-8220

Cell experiment:

A neurotoxic concentration of paraoxon (200 μM) is added to the granule cell cultures for the indicated time on day in vitro (DIV) 8. The following drugs are added to the granule cell cultures prior to or after paraoxon exposure on DIV 8: Ro-81-3220 (1 μM) is added 15 min prior to or 3 h after the addition of paraoxon. TPA (0.1 μM) is added 15 min prior to the addition of paraoxon[1].

Animal experiment:

Mice[4]The affects of long-term Ro 31-8220 administration over 4 to 6 weeks in MLP−/− heart failure mice are investigated. All mice are assessed for ventricular performance by echocardiography at the beginning of the study and 6 weeks later. Ro 31-8220 (or vehicle) is injected subcutaneously once per day at a dosage of 6 mg/kg/d[4].

References:

[1]. Wilkinson SE, et al. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J. 1993 Sep 1;294 ( Pt 2):335-7.
[2]. Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
[3]. Tian F, et al. Inhibition of protein kinase C protects against paraoxon-mediated neuronal cell death. Neurotoxicology. 2007 Jul;28(4):843-9. Epub 2007 Apr 20.
[4]. Hambleton M, et al. Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation. 2006 Aug 8;114(6):574-82.

Chemical Properties of Ro 31-8220

Cas No. 125314-64-9 SDF
المرادفات Bisindolylmaleimide IX
Chemical Name 3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate
Canonical SMILES CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)CCCSC(=N)N
Formula C25H23N5O2S M.Wt 457.55
الذوبان Soluble in DMSO Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of Ro 31-8220

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.1856 mL 10.9278 mL 21.8555 mL
5 mM 0.4371 mL 2.1856 mL 4.3711 mL
10 mM 0.2186 mL 1.0928 mL 2.1856 mL
  • حاسبة المولارية

  • حاسبة التخفيف

  • Molecular Weight Calculator

كتلة
=
تركيز
x
مقدار
x
ميغاواط *
 
 
 
** عند إعداد حلول المخزون، دائمًا استخدم الوزن الجزيئي الخاص بالدفعة للمنتج على ملصق القارورة MSDS / CoA (متوفر عبر الإنترنت).

احسب

In vivo Formulation Calculator (Clear solution) of Ro 31-8220

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

مراجعات

Review for Ro 31-8220

Average Rating: 5 ★★★★★ (Based on Reviews and 38 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ro 31-8220

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.